Zhenping Zhu

Double Helix (United States) — United States

Medicine · Health Sciences

66h-index22.5kcitations249works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(83), Angiogenesis and VEGF in Cancer(64), Glycosylation and Glycoproteins Research(39), HER2/EGFR in Cancer Research(23), Cancer, Hypoxia, and Metabolism(19)

Publications249 total

Abstract 4772: AI-guided engineering and preclinical development of biparatopic anti-DLL3 antibody-drug conjugates (ADCs)
Cancer Research·2025
Abstract 6072: Engineering and preclinical development of an anti-TROP2/PD-L1 bispecific antibody drug conjugate (ADC) for enhanced anti-tumor efficacy
Cancer Research·2025
Abstract 7315: Engineering and characterization of novel T cell engagers (TCEs) directed against colorectal cancer-associated antigens (CEACAM5, CDH17)
Cancer Research·2025
Abstract 7319: AI-guided engineering and development of anti-DLL3-targeting T cell engagers (TCEs)
Cancer Research·2025
Abstract 3499: Engineering and construction of anti-B7-H3 antibody-based T cell engagers (TCEs) and antibody-drug conjugates (ADCs) for cancer therapy
Cancer Research·2025
P0848 Engineering and Development of a Novel Bispecific Antibody Targeting both TL1A and α4β7 for the Treatment of IBD
Journal of Crohn s and Colitis·2025· 2 citedOpen Access
AN ANALYSIS OF THE EVOLUTION OF LOTUS IMAGES IN TRADITIONAL CHINESE ART AND THEIR BOTANICAL CAUSES
Trames Journal of the Humanities and Social Sciences·2024· 1 citedOpen Access
Correction: Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C
Journal of Cell Science·2023Open Access
The mechanism of action and biodistribution of a novel EGFR/VEGF bispecific fusion protein that exhibited superior antitumor activities
Heliyon·2023· 3 citedOpen Access
Data from Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
2023Open Access
Supplementary Data from Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
2023Open Access
Data from Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
2023Open Access
Supplementary Data from Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells
2023Open Access
Supplementary Figure 5A and 5B from Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
2023Open Access
Supplementary Figure 7A and 7B from Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
2023Open Access
Supplementary Figure 6A and 6B from Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
2023Open Access
Supplementary Figure 7A and 7B from Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
2023Open Access
Supplementary Figure 2 from Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1
2023Open Access
Data from Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1
2023Open Access
Supplementary Figure 1 from Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Larry Witte(19), Daniel J. Hicklin(16), Yan Wu(10), Shahin Rafii(9), Peter Böhlen(9), Koichi Hattori(8), Beate Heissig(8), Zhenyu Liu(8), Malcolm A.S. Moore(7), Sérgio Dias(7), Dale L. Ludwig(7), Xenia Jimenez(6), David Lyden(5), Rajiv Bassi(5), Paul Balderes(5), Shoujun Liu(5), Hongxian Niu(5), Neil R. Hackett(4), Ronald G. Crystal(4), Marie Prewett(4)